Latest Geron Corp (GERN) Headlines Downgrade Al
Post# of 119
Posted On: 03/13/2014 8:54:52 AM
Latest Geron Corp (GERN) Headlines
Downgrade Alert for Geron (GERN)
Comtex SmarTrend(R) - 51 mins ago
Geron (NASDAQ:GERN) was downgraded from Buy to Hold at Needham today. The stock closed yesterday at $1.69 on volume of 46.5 million shares, above average daily volume of 4.7 million. In the past 52 weeks, shares of Geron have traded between a low of $0.91 and a high of $7.79 and closed yesterday at $1.69, which is 86% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.1% while the 50-day MA has declined 1.8%.
GERON INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Geron Corporation Following FDA Clinical Hold of Blood Medicine and Analyst Downgrade
Business Wire - Wed Mar 12, 9:00PM CDT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Geron Corporation (Nasdaq: GERN).
Why Geron, Express, and Herbalife Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 12, 7:30PM CDT
The stock market demonstrated its continuing confusion Wednesday, initially falling sharply on ongoing concerns about tension in the Crimea and Chinese economic sluggishness. Yet by the end of the day, the S&P 500 had actually managed to post a ...
SHAREHOLDER ALERT: Investigation of Geron Corporation Announced by Law Offices of Howard G. Smith
Business Wire - Wed Mar 12, 7:15PM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Geron's operations and financial prospects.
Geron Is Dead in the Water, but Not Sunk Yet
David Williamson, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Onetime stem cell stalwart Geron Corp. , which has since reinvented itself as an oncology company, may have just lost its only oncology drug. The stock plunged 60% today after the FDA placed a total clinical hold on imetelstat in both of its phase...
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
PulteGroup and Herbalife are big market movers
AP - Wed Mar 12, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily XXX on the New York Stock Exchange and the Nasdaq Stock Market:
Why Geron Corporation Shares Were Mauled
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 11:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Geron , a clinical-stage biopharmaceutical...
Stock to Watch: Geron Down 66.6% (GERN)
Comtex SmarTrend(R) - Wed Mar 12, 10:10AM CDT
Geron (NASDAQ:GERN) is one of today's worst performing low-priced stocks, down 66.6% to $1.47 on 4.6x average daily volume. Thus far today, Geron has traded 22.6 million shares, vs. average volume of 4.9 million shares per day. The stock has underperformed the Dow (-66.6% to the Dow's -0.2%) and underperformed the S&P 500 (-66.6% to the S&P's -0.2%) during today's trading.
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Geron, Zogenix, Synta Pharmaceuticals, and Pfizer: Today’s Top Health Care Stories
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 12, 8:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Geron , ...
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma
Thomson Reuters ONE - Wed Mar 12, 4:00AM CDT
Conference Call Today, March 12, at 8:30 a.m. EDT
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2013 Financial Results
Thomson Reuters ONE - Wed Mar 05, 6:30AM CST
Menlo Park, Calif., March 5, 2014 - Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2013, on Wednesday, March 12, 2014, after the market close. Geron's management will also host a conference call for analysts and investors on Wednesday, March 12, 2014, at 4:30 p.m. Eastern Time to discuss the company's fourth quarter and annual results and recent events.
Form 4: Update Filing for Arrows Electronics Inc (ARW)
Vickers Stock Research - Thu Feb 27, 10:25AM CST
MENLO PARK, Calif., February 27, 2013 - Geron Corporation (Nasdaq: GERN) today announced that Olivia Bloom, Senior Vice President, Finance, and Chief Financial Officer, will present an overview of the company at 10:40 a.m. Eastern Time on Wednesday, March 6, at the Cowen and Company 33rd Annual Health Care Conference in Boston.
Downgrade Alert for Geron (GERN)
Comtex SmarTrend(R) - 51 mins ago
Geron (NASDAQ:GERN) was downgraded from Buy to Hold at Needham today. The stock closed yesterday at $1.69 on volume of 46.5 million shares, above average daily volume of 4.7 million. In the past 52 weeks, shares of Geron have traded between a low of $0.91 and a high of $7.79 and closed yesterday at $1.69, which is 86% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.1% while the 50-day MA has declined 1.8%.
GERON INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Geron Corporation Following FDA Clinical Hold of Blood Medicine and Analyst Downgrade
Business Wire - Wed Mar 12, 9:00PM CDT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Geron Corporation (Nasdaq: GERN).
Why Geron, Express, and Herbalife Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 12, 7:30PM CDT
The stock market demonstrated its continuing confusion Wednesday, initially falling sharply on ongoing concerns about tension in the Crimea and Chinese economic sluggishness. Yet by the end of the day, the S&P 500 had actually managed to post a ...
SHAREHOLDER ALERT: Investigation of Geron Corporation Announced by Law Offices of Howard G. Smith
Business Wire - Wed Mar 12, 7:15PM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Geron's operations and financial prospects.
Geron Is Dead in the Water, but Not Sunk Yet
David Williamson, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Onetime stem cell stalwart Geron Corp. , which has since reinvented itself as an oncology company, may have just lost its only oncology drug. The stock plunged 60% today after the FDA placed a total clinical hold on imetelstat in both of its phase...
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
PulteGroup and Herbalife are big market movers
AP - Wed Mar 12, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily XXX on the New York Stock Exchange and the Nasdaq Stock Market:
Why Geron Corporation Shares Were Mauled
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 11:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Geron , a clinical-stage biopharmaceutical...
Stock to Watch: Geron Down 66.6% (GERN)
Comtex SmarTrend(R) - Wed Mar 12, 10:10AM CDT
Geron (NASDAQ:GERN) is one of today's worst performing low-priced stocks, down 66.6% to $1.47 on 4.6x average daily volume. Thus far today, Geron has traded 22.6 million shares, vs. average volume of 4.9 million shares per day. The stock has underperformed the Dow (-66.6% to the Dow's -0.2%) and underperformed the S&P 500 (-66.6% to the S&P's -0.2%) during today's trading.
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Geron, Zogenix, Synta Pharmaceuticals, and Pfizer: Today’s Top Health Care Stories
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 12, 8:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Geron , ...
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma
Thomson Reuters ONE - Wed Mar 12, 4:00AM CDT
Conference Call Today, March 12, at 8:30 a.m. EDT
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2013 Financial Results
Thomson Reuters ONE - Wed Mar 05, 6:30AM CST
Menlo Park, Calif., March 5, 2014 - Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2013, on Wednesday, March 12, 2014, after the market close. Geron's management will also host a conference call for analysts and investors on Wednesday, March 12, 2014, at 4:30 p.m. Eastern Time to discuss the company's fourth quarter and annual results and recent events.
Form 4: Update Filing for Arrows Electronics Inc (ARW)
Vickers Stock Research - Thu Feb 27, 10:25AM CST
MENLO PARK, Calif., February 27, 2013 - Geron Corporation (Nasdaq: GERN) today announced that Olivia Bloom, Senior Vice President, Finance, and Chief Financial Officer, will present an overview of the company at 10:40 a.m. Eastern Time on Wednesday, March 6, at the Cowen and Company 33rd Annual Health Care Conference in Boston.
(0)
(0)Geron Corporation (GERN) Stock Research Links
Scroll down for more posts ▼